Feature

Of ‘miracles’ and money: Why hemophilia drugs are so expensive


 

Sitting at a picnic bench at a park, Jessica Morris pages through Landon’s insurance documents. Over the past year, his care cost over $120,000. She wonders sometimes what would happen if they lost their coverage.

“How much would you be willing to pay to have your child lead a normal life?” she said. “I don’t think that there’s anything we wouldn’t pay or sacrifice for him.”

It’s a problem she prays they’ll never have to face.

Kaiser Health News is a nonprofit news service covering health issues. It is an editorially independent program of the Kaiser Family Foundation that is not affiliated with Kaiser Permanente. KHN’s coverage of prescription drug development, costs, and pricing is supported by the Laura and John Arnold Foundation.

Pages

Recommended Reading

FDA approves Rebinyn for hemophilia B treatment
MDedge Family Medicine
Prophylactic emicizumab cut bleeds by 87% in hemophilia A with inhibitors
MDedge Family Medicine
Monthly fitusiran showed promise in small phase I hemophilia trial
MDedge Family Medicine
Vaccination does not eliminate risk for meningococcal disease in eculizumab recipients
MDedge Family Medicine
Study advances noninvasive prenatal testing for hemophilia
MDedge Family Medicine
Empagliflozin’s heart failure benefits linked to volume drop
MDedge Family Medicine
Gene therapy found promising in patients with hemophilia B
MDedge Family Medicine
FDA grants breakthrough therapy designation for severe aplastic anemia drug
MDedge Family Medicine
Gene therapy moves from promise to reality
MDedge Family Medicine
States strive to curb costs for a crucial – but exorbitant – hemophilia treatment
MDedge Family Medicine